[go: up one dir, main page]

ECSP13012398A - Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero - Google Patents

Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero

Info

Publication number
ECSP13012398A
ECSP13012398A ECSP13012398A ECSP13012398A EC SP13012398 A ECSP13012398 A EC SP13012398A EC SP13012398 A ECSP13012398 A EC SP13012398A EC SP13012398 A ECSP13012398 A EC SP13012398A
Authority
EC
Ecuador
Prior art keywords
conjugate
formula
ifn
peg
interferon
Prior art date
Application number
Other languages
English (en)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Dmitriy Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of ECSP13012398A publication Critical patent/ECSP13012398A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está relacionada a la industria farmacéutica y medicina, en particular, al nuevo PEG-interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad de interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco-kinéticos mejorados de fórmula general. Donde:n- valores integrales de 227 a 10 000, así que el peso molecular de PEG es de alrededor de 10 000 - 40 000 Da;m - integer ? 4;IFN - natural o recombinante polipéptido teniendo la actividad de IFN-alfa.También, la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG-IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales y cáncer, también enfermedades asociadas con inmunodeficiencia primaria o secundaria. La invención está relacionada al uso de conjugado de fórmula (1) en productos medicinales, los cuales tienen actividad antiviral, antiproliferativa e inmunomodulatoria, aproximaciones y/o tratamiento de enfermedades asociadas con inmunodeficiencia primaria o secundaria de conjugado de fórmula (1) y al contenedor con tal composición farmacéutica.
ECSP13012398 2010-07-20 2013-01-18 Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero ECSP13012398A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (ru) 2010-07-20 2010-07-20 НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Publications (1)

Publication Number Publication Date
ECSP13012398A true ECSP13012398A (es) 2013-05-31

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012398 ECSP13012398A (es) 2010-07-20 2013-01-18 Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero

Country Status (20)

Country Link
KR (1) KR101586372B1 (es)
CN (1) CN102617736B (es)
AR (1) AR087227A1 (es)
BR (1) BRPI1101565A2 (es)
CO (1) CO6680611A2 (es)
CR (1) CR20130021A (es)
CU (1) CU24193B1 (es)
DO (1) DOP2013000002A (es)
EA (1) EA020257B1 (es)
EC (1) ECSP13012398A (es)
MX (1) MX2011007458A (es)
MY (1) MY168784A (es)
NI (1) NI201300008A (es)
PE (1) PE20131034A1 (es)
PH (1) PH12012502425A1 (es)
RU (1) RU2447083C1 (es)
SG (1) SG187117A1 (es)
UA (1) UA99766C2 (es)
UY (1) UY33525A (es)
WO (1) WO2012011836A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (ru) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ)
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
EA029498B1 (ru) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
AU2021258734A1 (en) * 2020-04-20 2023-01-05 Altum Pharmaceuticals Inc. Recombinant interferon
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EA200500475A1 (ru) * 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
EP1771197A2 (en) * 2004-06-30 2007-04-11 Egen Corporation Pegylated interferon alpha-1b
DE602006013151D1 (de) * 2005-07-19 2010-05-06 Nektar Therapeutics Verfahren zur herstellung von polymermaleimiden
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
CN101491682A (zh) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101591387A (zh) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 聚乙二醇化重组人干扰素ω偶合物
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
EA201100809A1 (ru) 2012-01-30
CU24193B1 (es) 2016-09-30
MX2011007458A (es) 2012-01-19
CN102617736A (zh) 2012-08-01
BRPI1101565A2 (pt) 2012-12-04
MY168784A (en) 2018-12-04
RU2447083C1 (ru) 2012-04-10
DOP2013000002A (es) 2013-09-15
CN102617736B (zh) 2015-11-25
CO6680611A2 (es) 2013-05-31
UA99766C2 (uk) 2012-09-25
KR20130056885A (ko) 2013-05-30
SG187117A1 (en) 2013-02-28
AR087227A1 (es) 2014-03-12
CU20130013A7 (es) 2013-04-19
EA020257B1 (ru) 2014-09-30
UY33525A (es) 2012-02-29
KR101586372B1 (ko) 2016-01-18
HK1170504A1 (zh) 2013-03-01
CR20130021A (es) 2013-02-20
RU2010129824A (ru) 2012-01-27
WO2012011836A1 (en) 2012-01-26
PH12012502425A1 (en) 2013-07-08
NI201300008A (es) 2014-05-26
PE20131034A1 (es) 2013-09-27

Similar Documents

Publication Publication Date Title
ECSP13012398A (es) Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero
US10544193B2 (en) Compositions and methods for treating diseases by inhibiting exosome release
MX2022006940A (es) Composiciones farmaceuticas.
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
MX2012007410A (es) Compuestos antivirales novedosos.
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
DOP2013000003A (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
JP2013542196A5 (es)
NZ599901A (en) Improved medicinal aerosol formulations
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
Bolhassani Target molecules and delivery vehicles for anti-HIV drugs in vitro and in vivo
EP4269424A1 (en) Novel antiviral compounds and use thereof
TH133837A (es)
WO2022229459A1 (en) Compound for treating covid-19 infections
EA202091320A1 (ru) Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия
RU2014116988A (ru) Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
AR122350A1 (es) Composiciones farmacéuticas
EA202090135A1 (ru) Новые составы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
RU2014140049A (ru) МОЛЕКУЛА ИНТЕРФЕРОНА-β-1a ЧЕЛОВЕКА, МОДИФИЦИРОВАННАЯ ПОЛИЭТИЛЕНГЛИКОЛЕМ, ОБЛАДАЮЩАЯ ПРОТИВОВИРУСНОЙ, ИММУНОМОДУЛИРУЮЩЕЙ И АНТИПРОЛИФЕРАТИВНОЙ АКТИВНОСТЯМИ, С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ, УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, УЛУЧШЕННЫМИ ФАРМАКОКИНЕТИЧЕСКИМИ И ФАРМАКОДИНАМИЧЕСКИМИ ПАРАМЕТРАМИ, ПРИГОДНАЯ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ
MY170516A (en) Recombinant live vectors and their use in pharmaceuticals compositions against hepatitis c virus